References
- Beeram M, Patnaik A, Rowinsky EK. Raf: A strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771–90.
- Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, . Phase I pharmacokinetic and pharmacody-namic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139–6.
- Dummer R, Robert C, Chapman PB, Sosman JA, Middleton M, Bastholt L, . AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multi-center, phase II study. J Clin Oncol 2008;26:(Abstract)9033.
- Agarwal R, Banergi U, Camidge CR, Brown KH, Cantarini CV, Morris C, . The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer. J Clin Oncol 2008;26: (Abstract)3535.
- Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16: 1425–33.
- Sarker D, Banergi U, Agarwal R. Relative oral bioavailability of the hydrogen sulphate (Hyd-sulfate) capsule and free-base suspension formulations of AZD6244 (ARRY-142886): A Phase I trial in patients with advanced cancer. Ann Oncol 2008;19:/viii153–viii165.
- Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803–12.
- Schad K, Baumann Conzett K, Zipser MC . MEK kinase inhibition (mitogen-activated protein/extracellular signal-regulated kinase kinase) by AZD6244 (ARRY-142886) results in severe disturbance of epidermal home-ostasis with acute inflammation and chronic maladaptation. 2008 (submitted).
- Ben Bassat H, Klein BY. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 2000;6:933–42.
- Wierzbicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 2006;155:213.
- Varani J, Kang S, Stoll S, Elder JT. Human psoriatic skin in organ culture: Comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology 1998;66:253–9.
- Powell TJ, Ben Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, . Growth inhibition of psoriatic kerati-nocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 1999;141:802–10.
- Autier J, Escudier B, Wechsler, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886–92.
- Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, . Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7:48–54.
- Sapadin AN, Fleishmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermtol 2006;54:258–65.